lenalidomide has been researched along with Leukemia, Plasmacytic in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (14.81) | 29.6817 |
| 2010's | 17 (62.96) | 24.3611 |
| 2020's | 6 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, H; Fujimori, C; Hagino, T; Hidai, H; Kurimoto, M; Motomura, S; Murai, Y; Osanai, S; Saga, R; Sano, S | 1 |
| Ahmad Asnawi, AW; Chong, SL; Koh, AZY; Lau, NS; Liew, PK; Md Fauzi, A; Selvaratnam, V; Tan, SM; Tang, ASO | 1 |
| Fujimoto, A; Hiramoto, N; Ishikawa, T; Matsushita, A | 1 |
| Palazzo, G | 1 |
| Hishizawa, M; Horisawa, Y; Kondo, T; Takaori-Kondo, A; Yamashita, K | 1 |
| Ito, R; Kawakami, K; Nakamura, A; Yamaguchi, T | 1 |
| Abu Zaanona, MI; Patel, P | 1 |
| Cao, Z; Tian, C; Yang, H; Zhang, Q; Zhang, Y; Zhu, L | 1 |
| Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
| Inui, Y; Kanakura, Y; Kataoka, S; Kawata, S; Kubo, M; Maeda, T; Matsunaga, H; Matsuura, N; Ueda, S | 1 |
| Agnelli, L; Benevolo, G; Boccadoro, M; Bringhen, S; Caravita, T; Cascavilla, N; Cavalli, M; D'Arena, G; Di Raimondo, F; Falcone, A; Filardi, N; Guariglia, R; Lerose, R; Levi, A; Mansueto, G; Martorelli, MC; Mina, R; Morabito, F; Musto, P; Neri, A; Nobile, F; Offidani, M; Olivieri, A; Omedè, P; Palumbo, A; Petrucci, MT; Pietrantuono, G; Simeon, V; Todoerti, K; Villani, O | 1 |
| Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Fabbro, SK; Kaffenberger, BH | 1 |
| Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Tomita, S; Wakabayashi, M | 1 |
| Alrajeh, A; Hanbali, A; Rasheed, W | 1 |
| Berno, T; Cortelazzo, S; DE March, E; Marabese, A; Meneghini, V; Mian, M; Mondello, P; Patriarca, F; Pescosta, N; Pizzolo, G; Semenzato, G; Tinelli, M; Turri, G; Zambello, R | 1 |
| Farhat, MM; Le Guern, A; Lebas, D; Modiano, P; Quinchon, JF | 1 |
| Attolico, I; Cifarelli, RA; Cimminiello, M; Discepoli, G; Olivieri, A | 1 |
| Medeiros, BC; Pretz, J | 1 |
| Chanan-Khan, A; Deeb, G; Lee, K; Miller, KC; Sher, T | 1 |
| Liedtke, M; Medeiros, BC | 1 |
| Bocchia, M; D'Arena, G; D'Auria, F; Defina, M; Gozzetti, A; Musto, P; Papini, G; Statuto, T; Steduto, T | 1 |
| Caravita, T; De Bellis, A; de Fabritiis, P; Dentamaro, T; Morino, L; Musto, P; Perrotti, A; Siniscalchi, A; Tendas, A | 1 |
| Miwa, A | 1 |
| Benson, DM; Smith, MK | 1 |
| D'Auria, F; Guariglia, R; Lerose, R; Martorelli, MC; Musto, P; Pietrantuono, G; Villani, O; Zonno, A | 1 |
3 review(s) available for lenalidomide and Leukemia, Plasmacytic
| Article | Year |
|---|---|
Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Thalidomide | 2013 |
Plasma cell leukaemia and other aggressive plasma cell malignancies.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2010 |
Plasma cell leukemia: concepts and management.
Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasms, Second Primary; Palliative Care; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
24 other study(ies) available for lenalidomide and Leukemia, Plasmacytic
| Article | Year |
|---|---|
[Multiple extramedullary plasmacytomas responding to a reduced dose of carfilzomib following drug-induced thrombotic microangiopathy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Multiple Myeloma; Plasmacytoma; Recurrence; Thrombotic Microangiopathies | 2022 |
Plasma Cell Leukemia with Successful Upfront Venetoclax in Combination with Allogeneic Transplantation.
Topics: Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Transplantation, Homologous | 2023 |
[Successful treatment with lenalidomide-containing regimen of plasma cell leukemia accompanied by meningeal involvement].
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Middle Aged; Prognosis | 2019 |
[Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.]
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Oligopeptides; Plasma Cells; Recurrence | 2020 |
A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.
Topics: ADP-ribosyl Cyclase 1; Allografts; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bortezomib; Combined Modality Therapy; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Membrane Glycoproteins; Middle Aged; Molecular Targeted Therapy; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2020 |
[Successful disease control of plasma cell leukemia by the treatment comprising proteasome inhibitors, followed by daratumumab, lenalidomide, and dexamethasone therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Middle Aged; Proteasome Inhibitors | 2020 |
Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Oncogene Proteins, Fusion; Sulfonamides; Translocation, Genetic; Transplantation, Autologous; Treatment Failure | 2021 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bortezomib; Combined Modality Therapy; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pneumonia; Recombinant Fusion Proteins; Recurrence; Salvage Therapy; Syndecan-1; Thalidomide; Transplantation, Autologous | 2017 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Thalidomide | 2014 |
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Hypertension, Pulmonary; Induction Chemotherapy; Lenalidomide; Leukemia, Plasma Cell; Male; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide | 2014 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Neoplasms, Second Primary; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Resident rounds part III: plasma cell leukemia with initial cutaneous presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bortezomib; Dexamethasone; Doxorubicin; Erythema; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Middle Aged; Renal Dialysis; Thalidomide; Vincristine | 2014 |
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Female; Humans; Immunohistochemistry; Lenalidomide; Leukemia, Plasma Cell; Leukocyte Common Antigens; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Pyrazines; Remission Induction; Thalidomide; Time Factors; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Plasma cell leukemia mimicking hairy cell leukemia.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Hairy Cell; Leukemia, Plasma Cell; Plasma Cells; Thalidomide | 2015 |
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Topics: Bortezomib; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Prognosis; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
[Cutaneous involvement in plasma cell leukaemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Leg; Lenalidomide; Leukemia, Plasma Cell; Leukemic Infiltration; Skin Neoplasms; Treatment Outcome | 2017 |
Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report.
Topics: Adult; Antineoplastic Agents; Female; Graft vs Leukemia Effect; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Thalidomide; Treatment Outcome | 2009 |
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Pulmonary Eosinophilia; Secondary Prevention; Thalidomide; Treatment Outcome | 2009 |
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasms, Second Primary; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2012 |
Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Eruptions; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Stevens-Johnson Syndrome; Thalidomide | 2012 |
[Diagnosis and treatment for plasma cell leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Plasma Cell; Melphalan; Pyrazines; Rituximab; Thalidomide | 2012 |
Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia.
Topics: Female; Humans; Kinetics; Lenalidomide; Leukemia, Plasma Cell; Middle Aged; Thalidomide; Treatment Outcome | 2007 |
Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Leukemia, Plasma Cell; Male; Recurrence; Salvage Therapy; Thalidomide | 2008 |